Cholinergic nerve terminal

The cholinergic nerve terminal comprises the presynaptic ending of a neuron (in both the peripheral and central nervous systems) that employs acetylcholine as its principal neurotransmitter[3][5][8]. These terminals contain the molecular machinery for ACh synthesis (choline acetyltransferase), vesicular storage (VAChT), regulated release, receptor activation, and rapid degradation (acetylcholinesterase). Cholinergic terminals mediate signal transduction at numerous sites such as neuromuscular junctions, autonomic ganglia, and central brain regions, and regulate diverse physiological functions including movement, autonomic tone, learning, and memory[5][6][7][8]. Dysfunction or degeneration of cholinergic nerve terminals is a hallmark of various neurodegenerative and motor diseases, notably Alzheimer’s and Lewy body disease[3][4]. Therapeutic strategies indirectly target cholinergic nerve terminals via drugs that modify ACh release, degradation, or postsynaptic receptor responses, but the term itself does not specify a unique, druggable protein target[5][7][8]. In summary, "cholinergic nerve terminal" is not a canonical molecular target but rather an anatomical/functional entity composed of several therapeutic targets (e.g., acetylcholine receptors, choline acetyltransferase, acetylcholinesterase, VAChT), each with distinct drug classes and roles.

Other names

cholinergic terminalcholinergic axon terminalpresynaptic cholinergic terminal

Inhibit ACh breakdown (acetylcholinesterase inhibitors) Modulate postsynaptic receptor response (receptor agonists/antagonists) Inhibit vesicle fusion/release (botulinum toxin)